Arovella Therapeutics - Recap of a busy quarter
Ahead of its FY22 results, Arovella has released its quarterly activities report, reiterating key developments and milestones achieved in the closing quarter of the financial year. While the key highlight was the signing of the manufacturing agreement with Q-Gen for its chimeric antigen receptor-invariant natural killer T (CAR-iNKT) programme ALA-101, initiation of commercial activities (with the launch of ZolpiMist in Australia) was another major milestone. Arovella also secured the US patent for Anagrelide (an under-development oral spray formulation for solid tumours), which expands on its existing patents in Europe, Japan and Australia. Additionally, Arovella announced its first ESG report, based on the World Economic Forum’s framework. The cash balance stood at A$6.1m at the end of Q422.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.